New Medical Solutions curates credible advances that solve real problems in healthcare—faster diagnosis, safer procedures, better monitoring, smoother coordination, and fairer access.
Jubilant HollisterStier, a CDMO unit of India’s Jubilant Pharmova, earned an FDA warning letter after inspectors found its Montreal production plant lacked appropriate quality control systems.
AdvanCell, a clinical-stage radiopharmaceutical outfit, inked a lease near Boston to produce its prostate cancer candidate and set roots down for its U.S. headquarters.
With interest in automated cell therapy production beginning to build from about 2016 onward, some 23 companies working in the field have now raised a collective $1.1 billion across 34 rounds through
Eighteen months after Novo Nordisk purchased a plant in the Czech Republic from Novavax, the Danish drugmaker said it is set to kick off the manufacturing of ingredients for next-generation diabetes and
Recipharm has sketched out a “multi-million-dollar” investment in its U.S. manufacturing operations as part of a move to boost its sterile fill-finish capabilities and other production offerings for customers.
As the United Kingdom juggles industry concerns about the region’s waning appeal and competitiveness, Eisai is getting a lift from a production-tinged fund that the British government first unveiled in 2024.
Hikma Pharmaceuticals plans to spend $267 million to expand a pair of manufacturing facilities in Ohio as part of the $1 billion the U.K. drugmaker committed a year ago to build out